Guest guest Posted July 16, 2010 Report Share Posted July 16, 2010 http://www.fiercebiotech.com/story/vivus-qnexa-takes-center-stage-during-panel-review/2010-07-15 "The company addressed some safety concerns during its presentation. Among during this morning's presentation, including psychiatric side effects, which it says were more frequent on Qnexa, but were typically mild and not associated with increased use of antidepressant medications. Furthermore, these events were identifiable early, and there was no increased risk of suicidality." Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.